Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 1999

View Archived Issues

Company Profile: Sunesis

Maxamine combination treatment for AML effective in phase II studies

Genzyme General and Genovo to collaborate on gene therapy for rare genetic diseases

Nabi hepatitis C drug shows promise in chimpanzee study

Licensing opportunity from NIH: drug delivery system for water-insoluble drugs

Licensing opportunity from NIH: thioester compounds for inactivating HIV

OSI establishes partnership with Tanabe Seiyaku for diabetes treatment

Ligand and Parke-Davis establish research collaboration

Regeneron provides interim data from phase I Axokine study and highlights further plans

Inex focuses on product progress during Q2 1999

Immunomedics awarded four grants from the NIH for development of cancer therapies

Promising results achieved in phase II study of thalidomide in multiple myeloma

Abbott continues to improve on cell adhesion inhibitors

First patient enrolled in York Medical's cancer vaccine trial

NOS-2 inhibition with aminoguanidine prevents vision loss in rat model of glaucoma

Brain GABA-A receptor ligands developed by Neurogen scientists

3-D discloses inhibitors of trypsin-like serine proteases

Hydroxamic and carboxylic acid-based MMP/TNF-alpha inhibitors center of focus at Darwin

Glaxo Wellcome patents improved adenosine A2A receptor agonists as antiinflammatory agents

New protein farnesyltransferase inhibitors in the AstraZeneca pipeline

Novel B-cell-selective immunomodulators useful in transplantation, autoimmune diseases

Potential new penciclovir prodrug developed at SK Chemicals proves effective and safe

3-Dimensional awarded two research grants from NIH

YM-31758: a potent and selective inhibitor of human prostatic 5alpha-reductase

New 4-pyrrolidinylthio carbapenem with balanced spectrum chosen for further studies

PTP1B inhibitors evaluated at Wyeth-Ayerst for potential as oral antidiabetic agents

Plant-derived CNS stimulant and cognition-enhancing agent under study in Brazil

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....